Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Būtiski notikumi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2011-12-08 15:59:04 |
Versijas komentārs | |
Teksts |
Olaine, December 8, 2011
Attached: presentation of the webinar Results for the first 9 months of 2011 show that sales of AS “Olainfarm” have grown by nearly 40% compared to the same period a year ago and have reached 26.3 million LVL (37.4 million EUR). Sales made during first 9 months of this year already exceed the sales made during the entire 2010 by more than one million lats.
Increase in sales directly influenced company’s profits, which during the third quarter of 2011 reached the best level so far of 1.8 million LVL (2.6 million EUR). The profit of the first 9 month period was 5 million LVL (7.1 million EUR).
On November 16, 2011 Board of the Company decided to increase annual sales and profit targets of the Company. The new sales target was set at 35 million LVL (49.8 million EUR) while the new profit target was set at 6.3 million LVL (8.96 million EUR). According to this unaudited report during 9 months of 2011 75% of revised sales targets and 80% of revised profit targets are met during 3 quarters of 2011.
AS Olainfarm is one of the biggest pharmaceutical companies in Latvia with nearly 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company's operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 30 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.
Information prepared by:
Salvis Lapins
Member of the Board
AS Olainfarm
Cell: +371 26448873
e-mail: “Olainfarm” announces new cooperation partners and forecasts
Today in Third Quarter 2011 Investor Conference Webinar the member of the management board Salvis Lapiņš presented analysis of third quarter financial results and announced AS “Olainfarm” expansion plans:
|
Pielikumi |